Clinical Trial Update: Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selumetinib sulfate in women with recurrent low-grade ovarian or peritoneal serous carcinomas has completed enrollment with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Ovarian Serous Tumor
• Borderline Ovarian Surface Epithelial-stromal Tumor
• Low-grade Ovarian Serous Adenocarcinoma
• Micropapillary Serous Carcinoma
• Peritoneal Carcinoma
• Peritoneal Low-grade Serous Adenocarcinoma

Drugs mentioned

• Selumetinib Sulfate (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-06-29